Gabather (GABA) Investor Update summary

Clinical development and pipeline progress

• Lead compound GT002 is in a fully funded phase 2 clinical trial for schizophrenia in Denmark, with results expected end of Q1 to mid-Q2 next year.

• GT002 has shown a unique neural fingerprint in imaging studies, leading to a provisional US patent application.

• The drug is well-tolerated, non-sedative, stable, and suitable for once-daily oral dosing.

• Additional pipeline compounds (e.g., GT005) are in preclinical stages, with potential for multiple neuropsychiatric indications.

• Early EEG readouts comparing GT002, placebo, and benzodiazepine will be available during the ongoing study.

Market opportunity and partnership strategy

• Neuropsychiatric disorders represent a large unmet medical need, with significant market potential for new therapies.

• GT002 is positioned as a first-in-class pro-cognitive GABA modulator, with no current equivalent treatments.

• Licensing or partnership discussions are ongoing with major pharma companies, aiming for a deal by Q3 next year.

• Example licensing deals in the sector can reach $500-600 million in total value, with substantial upfront payments.

• The company is actively participating in major industry meetings to attract partners and investors.

Patent and intellectual property updates

• A provisional US patent was filed for the unique neural fingerprint induced by GT002, covering both biomarker and therapeutic uses.

• Patent portfolio includes composition of matter, synthesis, formulation, and medical use patents, with coverage extending to 2029-2031.

• Ongoing efforts to expand patent protection as more clinical data becomes available.